Sanofi receives EU approval for diabetes drug Suliqua

Sanofi has announced that its new type 2 diabetes drug Suliqua has been approved by the European Commission.

The once-daily titratable fixed-ratio combination of basal insulin glargine and the GLP-1 receptor agonist lixisenatide has been approved for use with metformin to improve glycaemic control in patients who have not responded to other metformin-based treatment approaches.

This approval was based on data from two phase III studies, LixiLan-O and LixiLan-L, which enrolled more than 1,900 adults worldwide and showed that Suliqua delivered a statistically superior blood sugar reduction compared to other therapies.

Suliqua is designed to be delivered via two pre-filled SoloSTAR pens, providing different dosing options to address individual market and patient insulin needs.

Dr Elias Zerhouni, president for global research and development at Sanofi, said: "The approval of Suliqua represents the successful culmination of a concerted effort by Sanofi scientists to bring two injectable treatments together in a single and precisely titratable dose."

This comes after the drug was approved by the US Food and Drug Administration in November 2016.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.